Full-Time

Macro Trader

Posted on 6/27/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$120k - $225k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Hybrid

Four days in the office per week with one remote day.

Category
Quantitative Finance
Finance & Banking
Required Skills
Risk Management
Requirements
  • Minimum of 2 years' relevant experience trading currency, rates or commodity markets.
  • Strong academic credentials: an undergraduate degree is required; CFA/Masters degree would be viewed favorably.
  • Superior trade execution skills – The Trader will execute orders in a manner consistent with our best execution and risk management practices, as well as our policies and procedures.
  • Superior collaboration skills – The successful candidate will enjoy being an individual contributor within a highly collaborative team and embrace the benefits of overlapping lines of responsibility.
  • Growth mindset – The flexibility and openness to continue learning, evolving, and growing as a trader is required.
  • Impeccable integrity, fiduciary mindset, and ability to consistently place the interests of our clients as the number one priority.
  • Strong work ethic.
  • Ability to work quickly and accurately in a fast-paced, dynamic environment; and
  • A precision and risk management mindset that results in accurate and compliant work and manifests itself in double-checking work, stopping to question anything unusual, and frequent reconciliation of work throughout the day.
Responsibilities
  • Execute orders in a manner consistent with best execution and risk management practices, as well as policies and procedures, using a mix of high- and low-touch methods for all relevant accounts under management.
  • Gather, analyze, and disseminate pertinent market, sector and instrument related information that identifies actionable investment opportunities.
  • Develop an in-depth understanding of the various investment philosophies of our portfolio management teams to contribute to the investment dialogue.
  • Monitor and improve efforts to enhance efficiency while mitigating risk.
  • Collaborate with portfolio managers, strategists, analysts, and other traders; build strong external relationships with counterparties and internal relationships.
  • Solicit potential trade interest from portfolio managers internally and locate external supply.
  • Communicate action-oriented opinions clearly and with conviction and contribute to an open investment dialogue.
  • Display a growth mindset and global perspective for innovation in investment products and market structures.
  • Operate in a fast-paced, dynamic environment with a focus on accuracy and compliance.
Desired Qualifications
  • CFA or Masters degree would be viewed favorably.
  • Experience trading a wide array of instruments would be additive.
  • Working knowledge of programming languages (SQL, Python, R, MATLAB, etc.) and data analysis/visualization tools (Tableau, Qlik, etc.) would be additive.
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$61.8B

Headquarters

Boston, Massachusetts

Founded

1933

Your Connections

People at Wellington Management who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.3T platform supports cross-sell across institutional and wealth channels.[2][4]
  • Hartford Funds acquisition adds advisor distribution and strengthens US Wealth reach.[3]
  • Liquid alternatives and sustainable outcomes provide differentiated product demand.[1][3]

What critics are saying

  • AUM-linked fees fall quickly during market drawdowns and passive outflows.[3]
  • Hartford integration risks disrupt systems, talent retention, and client relationships.[3]
  • Regulatory approval delays can postpone or derail the Hartford transaction.[3]

What makes Wellington Management unique

  • Independent private partnership with globally integrated, research-driven boutiques.[3][6]
  • Broad platform spans equity, fixed income, alternatives, and multi-asset solutions.[2][3]
  • Long client relationships and local presence across major financial centers.[2][4]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.